Go Pro
→ Iran War Shock: What I Was Told In That Private Meeting (From Banyan Hill Publishing) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALPS
ALPS Group Inc Ordinary Share
$0.40
-1.0%		$0.39
$0.23
▼
$15.00
$65.89M-0.159,054 shs69,697 shs
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
$2.66
+2.3%		$2.76
$0.96
▼
$3.16
$60.51M-0.03114,319 shs255,396 shs
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
$11.51
$11.72
$11.41
▼
$18.72
$63.37M-0.0414,430 shsN/A
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
$2.95
+2.1%		$3.36
$1.83
▼
$24.60
$17.02M0.945,934 shs4,772 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALPS
ALPS Group Inc Ordinary Share
0.00%-1.00%-3.41%-38.13%+39,599,900.00%
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
0.00%-5.34%-6.99%+3.91%+132.31%
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
0.00%0.00%0.00%-6.18%-1.16%
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
0.00%-6.35%-13.74%-18.96%-86.21%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
ALPS
ALPS Group Inc Ordinary Share
$0.40
-1.0%		$0.39
$0.23
▼
$15.00
$65.89M-0.159,054 shs69,697 shs
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
$2.66
+2.3%		$2.76
$0.96
▼
$3.16
$60.51M-0.03114,319 shs255,396 shs
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
$11.51
$11.72
$11.41
▼
$18.72
$63.37M-0.0414,430 shsN/A
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
$2.95
+2.1%		$3.36
$1.83
▼
$24.60
$17.02M0.945,934 shs4,772 shs
7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
ALPS
ALPS Group Inc Ordinary Share
0.00%-1.00%-3.41%-38.13%+39,599,900.00%
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
0.00%-5.34%-6.99%+3.91%+132.31%
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
0.00%0.00%0.00%-6.18%-1.16%
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
0.00%-6.35%-13.74%-18.96%-86.21%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
ALPS
ALPS Group Inc Ordinary Share
1.00
SellN/AN/A
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
1.00
SellN/AN/A
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
2.00
HoldN/AN/A
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
2.00
Hold$23.00679.66% Upside

Current Analyst Ratings Breakdown

Latest NCEL, ALPS, KVAC, and BOLD Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/18/2026
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/29/2026
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (D-)
7/29/2026
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHold (C-) ➝ Hold (C)
7/13/2026
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E) ➝ Sell (E+)
7/13/2026
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
Laidlaw logo
Laidlaw
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$23.00
7/8/2026
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingHold (C-)
7/6/2026
ALPS
ALPS Group Inc Ordinary Share
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/29/2026
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E)
(Data available from 9/27/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
ALPS
ALPS Group Inc Ordinary Share
$4.86M13.56N/AN/A($3.10) per share-0.13
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
N/AN/AN/AN/A$4.41 per shareN/A
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/AN/AN/AN/AN/AN/A
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
N/AN/AN/AN/A$1.59 per shareN/A
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
ALPS
ALPS Group Inc Ordinary Share
-$2.01M$0.331.20N/AN/AN/AN/AN/AN/A
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
-$58.20M-$2.86N/AN/AN/AN/A-70.89%-47.37%N/A
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/AN/AN/AN/AN/AN/AN/AN/AN/A
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
-$8.30MN/AN/AN/AN/AN/AN/AN/AN/A

Latest NCEL, ALPS, KVAC, and BOLD Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/18/2026Q2 2026
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
N/A-$0.48N/A-$0.48N/AN/A
8/14/2026Q2 2026
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/A$0.08N/A$0.08N/AN/A
8/7/2026Q2 2026
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
N/A-$1.06N/A-$1.06N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
ALPS
ALPS Group Inc Ordinary Share
N/AN/AN/AN/AN/A
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
N/AN/AN/AN/AN/A
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/AN/AN/AN/AN/A
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
ALPS
ALPS Group Inc Ordinary Share
N/A
0.36
0.27
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
N/A
9.48
9.48
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/AN/AN/A
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
N/A
0.40
0.76

Institutional Ownership

CompanyInstitutional Ownership
ALPS
ALPS Group Inc Ordinary Share
27.90%
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
N/A
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
51.72%
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
N/A

Insider Ownership

CompanyInsider Ownership
ALPS
ALPS Group Inc Ordinary Share
25.52%
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
23.10%
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
80.20%
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
16.40%
CompanyEmployeesShares OutstandingFree FloatOptionable
ALPS
ALPS Group Inc Ordinary Share
89166.40 million123.94 millionN/A
Boundless Bio, Inc. stock logo
BOLD
Boundless Bio
2822.75 million17.49 millionNo Data
Keen Vision Acquisition Corporation stock logo
KVAC
Keen Vision Acquisition
N/A5.51 million1.09 millionNot Optionable
NLS Pharmaceutics Ltd. stock logo
NCEL
NLS Pharmaceutics
65.78 million4.83 millionNot Optionable

Recent News About These Companies

Der aktuelle Kurs der NewcelX AG Aktie beträgt 3,380.
August 27, 2026  |  de.investing.comhttps://de.investing.com/equities/nls-pharmaceutics-ag
NewcelX Announces Pricing of $1.4 Million Equity Financing at 20% Premium Pricing
July 31, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/31/3336827/0/en/newcelx-announces-pricing-of-1-4-million-equity-financing-at-20-premium-pricing.html
NewcelX Appoints World-Renowned Diabetes Cure-Focused Pioneer, Dr. Camillo Ricordi, to Scientific Advisory Board
July 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3324174/0/en/newcelx-appoints-world-renowned-diabetes-cure-focused-pioneer-dr-camillo-ricordi-to-scientific-advisory-board.html
NewcelX Announces Successful FDA Pre-IND Meeting with Clear Path Forward for NCEL-101 Toward Starting Clinical Trials for Type 1 Diabetes
July 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/01/3320694/0/en/newcelx-announces-successful-fda-pre-ind-meeting-with-clear-path-forward-for-ncel-101-toward-starting-clinical-trials-for-type-1-diabetes.html
NewcelX Publishes Peer-Reviewed Study Demonstrating Broad Therapeutic Potential of its Stem Cell Technology Platform
June 15, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/06/15/3311778/0/en/newcelx-publishes-peer-reviewed-study-demonstrating-broad-therapeutic-potential-of-its-stem-cell-technology-platform.html
NewCelX Ltd. Submits Pre-IND Package to the FDA for NCEL-101 for the Treatment of Type 1 Diabetes
May 27, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/05/27/3301840/0/en/newcelx-ltd-submits-pre-ind-package-to-the-fda-for-ncel-101-for-the-treatment-of-type-1-diabetes.html
NewcelX Reports Financial Results for 2025 and Provides Shareholders with Update on Accelerated Development of Type 1 Diabetes Treatment in Collaboration with Eledon Pharmaceuticals in 2026
April 30, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3284829/0/en/newcelx-reports-financial-results-for-2025-and-provides-shareholders-with-update-on-accelerated-development-of-type-1-diabetes-treatment-in-collaboration-with-eledon-pharmaceutical.html
Michel Revel Purchases 54,545 Shares of NLS Pharmaceutics (NASDAQ:NCEL) Stock
April 30, 2026  |  insidertrades.comhttps://www.insidertrades.com/alerts/nasdaq-ncel-insider-buying-and-selling-2026-04-30/
NewcelX Updates Corporate Presentation to Highlight Type 1 Diabetes Flagship Program Following Strategic Collaboration with Eledon Pharmaceuticals Ahead of Swiss Biotech Conference
April 20, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/20/3276901/0/en/newcelx-updates-corporate-presentation-to-highlight-type-1-diabetes-flagship-program-following-strategic-collaboration-with-eledon-pharmaceuticals-ahead-of-swiss-biotech-conference.html
NewcelX Announces Pricing of $1.35 Million Equity Financing at 30% Premium Pricing
April 1, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/01/3266497/0/en/newcelx-announces-pricing-of-1-35-million-equity-financing-at-30-premium-pricing.html
NewcelX Announces Strategic Collaboration with Eledon Pharmaceuticals to Advance NCEL-101 Program for Type 1 Diabetes
March 9, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/newcelx-announces-strategic-collaboration-with-eledon-pharmaceuticals-to-advance-ncel-101-program-for-type-1-diabetes-302708071.html
NewcelX Reports Peer-Reviewed Publication Supporting Mazindol IR/SR and Advances CVR Monetization Strategy
February 12, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/newcelx-reports-peer-reviewed-publication-supporting-mazindol-irsr-and-advances-cvr-monetization-strategy-302686180.html
NewcelX Announces Updated Corporate Presentation Ahead of Key Spring 2026 Investor and Partnering Conferences
January 29, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/newcelx-announces-updated-corporate-presentation-ahead-of-key-spring-2026-investor-and-partnering-conferences-302673887.html
NewcelX Announce Positive Results from International Collaborative Study Exploring Advanced Biomaterial Approaches for Stem Cell-Derived Islet Delivery in Type 1 Diabetes Without Immune Suppression
January 12, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/newcelx-announce-positive-results-from-international-collaborative-study-exploring-advanced-biomaterial-approaches-for-stem-cellderived-islet-delivery-in-type-1-diabetes-without-immune-suppression-302658361.html
NewcelX Appoints Dr. Julien Boisdron, a Swiss Big Pharma Leader in Diabetes Innovation, to Its Scientific Advisory Board
January 5, 2026  |  prnewswire.comhttps://www.prnewswire.com/news-releases/newcelx-appoints-dr-julien-boisdron-a-swiss-big-pharma-leader-in-diabetes-innovation-to-its-scientific-advisory-board-302652531.html
NewcelX Expands Intellectual Property Footprint with Publication of DOXA Patent Application in China
December 11, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/newcelx-expands-intellectual-property-footprint-with-publication-of-doxa-patent-application-in-china-302638937.html
NewCelX Appoints EY as New Auditor Following Merger
November 20, 2025  |  tipranks.comhttps://www.tipranks.com/news/company-announcements/newcelx-appoints-ey-as-new-auditor-following-merger?utm_source=marketbeat.com&utm_medium=referral
NewcelX Strengthens Scientific Advisory Board with Appointment of Jeremy Shefner, MD, PhD, Chief Medical Officer at the Barrow Neurological Institute
November 17, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/newcelx-strengthens-scientific-advisory-board-with-appointment-of-jeremy-shefner-md-phd-chief-medical-officer-at-the-barrow-neurological-institute-302616848.html
NewcelX Announces Scientific Leadership with the Head of Division of Medical Neurosciences at the Department of Neurology at Hadassah, Prof. Tamir Ben-Hur on Its Scientific Advisory Board
November 6, 2025  |  prnewswire.comhttps://www.prnewswire.com/news-releases/newcelx-announces-scientific-leadership-with-the-head-of-division-of-medical-neurosciences-at-the-department-of-neurology-at-hadassah-prof-tamir-ben-hur-on-its-scientific-advisory-board-302606998.html
NewcelX Ltd.
November 5, 2025  |  cnn.comhttps://www.cnn.com/markets/stocks/NCEL

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Data center hallway with rows of server racks and cables, plus a monitoring room with computer screens in the background.
AI Token Costs Are Changing the Hardware vs. Software Debate
By Jeffrey Neal Johnson | September 6, 2026
A Tesla concept vehicle with illuminated front light bar drives on a road against a city skyline at dusk.
Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
By Sam Quirke | September 8, 2026
Micron, Coherent and Tower Semiconductor: 3 Stocks Built on AI's Bottlenecks
NVIDIA Just Named AI's Next Bottleneck—And These 3 Stocks Sit Right In It
By Bridget Bennett | September 20, 2026
A quantum computing chandelier housed in glass enclosure inside a facility, with a military jet visible outside.
IBM and Lockheed Martin Turn a Swiss Defense Deal Into a Quantum Computing Bet
By Jeffrey Neal Johnson | September 11, 2026
An F-35 fighter jet sits inside a military aircraft manufacturing or maintenance hangar facility.
3 European Defense Stocks Raising Guidance While the Sector Lags
By Dan Schmidt | September 14, 2026

ALPS Group Inc Ordinary Share NASDAQ:ALPS

$0.39 -0.01 (-1.50%)
As of 09/25/2026 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

ALPS Group Inc is a fully integrated platform encompassing biotechnology research, medical, and wellness services specializing in predictive, precision and preventive health management. It aims to provide its clientele with access to DNA and mRNA sequencing, cellular therapy, as well as wellness and anti-aging products and services.

Boundless Bio stock logo

Boundless Bio NASDAQ:BOLD

$2.66 +0.06 (+2.31%)
Closing price 09/25/2026 04:00 PM Eastern
Extended Trading
$2.66 -0.01 (-0.19%)
As of 09/25/2026 05:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Boundless Bio Inc is a clinical-stage oncology company. The company is dedicated to unlocking a new paradigm in cancer therapeutics that addresses the unmet need in patients with oncogene-amplified tumors by targeting extrachromosomal DNA (ecDNA), a root cause of oncogene amplification observed in cancer patients. Its ecDTx, BBI-355, is a novel, oral, selective inhibitor of checkpoint kinase 1 (CHK1), which manages ecDNA replication and transcription in cancer cells.

Keen Vision Acquisition stock logo

Keen Vision Acquisition NASDAQ:KVAC

$11.51 0.00 (0.00%)
As of 09/25/2026

Keen Vision Acquisition Corporation does not have significant operations. The company intends to effect a merger, share exchange, asset acquisition, share purchase, recapitalization, reorganization, and related business combination with one or more businesses or entities. It also intends to focus on businesses in the biotechnology, consumer goods, and agriculture sectors. The company was incorporated in 2021 and is based in Summit, New Jersey.

NLS Pharmaceutics stock logo

NLS Pharmaceutics NASDAQ:NCEL

$2.95 +0.06 (+2.08%)
As of 09/25/2026 03:54 PM Eastern

NLS Pharmaceutics AG, a clinical-stage biopharmaceutical company, engages in the discovery and development of therapies for patients with rare and complex central nervous system disorders. The company is focusing on the development of treatments for narcolepsy, idiopathic hypersomnia, and other rare sleep disorders, as well as neurodevelopmental disorders, such as attention deficit hyperactivity disorder (ADHD). Its lead product candidates include Quilience to treat excessive daytime sleepiness and cataplexy; and Nolazol for the treatment of ADHD. The company also developing NLS-4, a selective dopamine reuptake inhibitor to prevent rare sleep disorders; NLS-3, a repurposed reverse ester of methylphenidate for treatment of ADHD; NLS-8, a melatonin ML1A receptor agonist, improved scopolamine-induced amnesia; NLS-11, a norepinephrine and dopamine reuptake inhibitor and muscarinic M1, M2, M3 receptor antagonist; and NLS-12, a norepinephrine and dopamine reuptake inhibitor and muscarinic M4 receptor antagonist. NLS Pharmaceutics AG was incorporated in 2015 and is based in Zurich, Switzerland.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas